Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Vincenzi
Bruno
B
Santini
Daniele
D
La Cesa
Annalisa
A
Tonini
Giuseppe
G
D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000556:secondary* / Q000628:therapy; D004164:Diphosphonates / Q000627:therapeutic use*; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D007680:Kidney Neoplasms / Q000473:pathology* / Q000628:therapy; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D012494:Sampling Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D000077211:Zoledronic Acid
D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid